EPRX logo

EPRX
Eupraxia Pharmaceuticals Inc

152
Mkt Cap
$434.21M
Volume
126,659.00
52W High
$9.32
52W Low
$3.67
PE Ratio
-7.12
EPRX Fundamentals
Price
$7.06
Prev Close
$7.02
Open
$7.08
50D MA
$7.57
Beta
0.59
Avg. Volume
231,875.53
EPS (Annual)
-$1.03
P/B
7.01
$248.55
Loading...
Loading...
News
all
press releases
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Receives Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a report on Wednesday...
MarketBeat·23h ago
News Placeholder
More News
News Placeholder
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to "Sell" at Wall Street Zen
Wall Street Zen raised Eupraxia Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday...
MarketBeat·5d ago
News Placeholder
New Strong Sell Stocks for April 2nd
ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.
Zacks·21d ago
News Placeholder
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 26.3% in March
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,500,950 shares, an increase of 26.3% from the February 26th total of 1,979,996 shares. Approximately...
MarketBeat·24d ago
News Placeholder
Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Tuesday
Eupraxia Pharmaceuticals (NASDAQ:EPRX) will be releasing earnings before the market opens on Tuesday, March 31. (View Earnings Report at...
MarketBeat·1mo ago
News Placeholder
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.read more...
Benzinga·1mo ago
News Placeholder
William Blair Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX)
William Blair assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Monday. They issued an "outperform" rating for the company...
MarketBeat·1mo ago
News Placeholder
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings Results, Misses Estimates By $0.21 EPS
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.21...
MarketBeat·1mo ago
News Placeholder
Lifesci Capital Has Negative Outlook of EPRX FY2026 Earnings
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Analysts at Lifesci Capital dropped their FY2026 earnings per share estimates for shares of Eupraxia Pharmaceuticals in a research note issued to investors on Monday, March 16th. Lifesci Capital analyst S. Slutsky now forecasts that the com...
MarketBeat·1mo ago
News Placeholder
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Lowered by Zacks Research
Zacks Research downgraded Eupraxia Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Tuesday...
MarketBeat·1mo ago
<
1
2
...
>

Latest EPRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.